bioMérieux (BIM) H2 2025 earnings summary

Executive summary

• Achieved €4,070 million in sales for 2025, representing 6.2% organic growth, outpacing a 1% market increase, with strong contributions from new product launches, acquisitions, and automation initiatives.

• Contributive EBIT (CEBIT) reached €728 million (17.9% of sales), up 16% organically, driven by operational simplification, innovation, and margin improvement.

• Free cash flow surged 40% to €462 million, reflecting robust cash generation and disciplined capital allocation.

• Adjusted EPS increased 9% to €4.64; adjusted net income up 9.4% to €552 million.

• Significant CSR progress, with a 28–29% reduction in greenhouse gas emissions since 2019, while sales grew 50%.

Financial highlights

• Gross profit margin improved to 56.7% of sales, up 90 basis points like-for-like, driven by product mix and efficiency gains.

• EBITDA reached €960 million (23.6% of sales), up 10% organically; adjusted EPS rose 9% to €4.64.

• Dividend proposed at €0.98 per share, up 9% from the prior year.

• CapEx at €328–335 million (8–8.2% of sales), focused on manufacturing automation and instrument placement.

• Net cash position at €108 million at year-end.

Outlook and guidance

• 2026 organic sales growth expected between 5% and 7%, with CEBIT to increase by at least 10%.

• Key growth drivers: BIOFIRE® non-respiratory panels (~10%), SPOTFIRE® (40–60%), Microbiology (3–5%), Industrial Applications (7–9%).

• Respiratory panels expected between -3% and +3%, immunoassays -5% to 0%.

• Currency effects estimated to negatively impact EBIT/CEBIT by €50–60 million.

• Strategic plan targets 7% CAGR sales growth and 10% annual CEBIT growth through 2028.